Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.69 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.69 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.69 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.69 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.69 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.69 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.69 |
| ▸ | TFPI | P10646 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.50 |
| ▸ | PTH1R | Q03431 | 3/20 | 0.49 |
| ▸ | VIPR1 | P32241 | 3/20 | 0.48 |
| ▸ | VIPR2 | P41587 | 3/20 | 0.47 |
| ▸ | HRAS | P01112 | 1/20 | 0.47 |
| ▸ | KRAS | P01116 | 1/20 | 0.47 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.47 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Conantokin G SCHEMBL29405425 | 1.00 | GRIN2D (0.69) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL30546034 | 0.98 | GRIN2D (0.71) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL31202698 | 0.95 | GRIN2D (0.66) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL30463853 | 0.94 | GRIN2D (0.64) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL30296729 | 0.92 | GRIN2D (0.61) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL29489382 | 0.90 | GRIN2D (0.59) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL31578281 | 0.89 | GRIN2D (0.57) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL29489379 | 0.86 | GRIN2D (0.55) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL30567452 | 0.85 | TFPI (0.58) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL30176466 | 0.85 | RXFP1 (0.54) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264860-A2 | METHODS OF TREATING POST-COVID AIRWAY DISEASE | YALE UNIVERSITY (US) | 2025-12-26 | — | — | WO | claimed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260062709-A1 | METHODS FOR IMPROVING PRODUCTION OF BIOLOGICAL PRODUCTS BY REDUCING THE LEVEL OF ENDOGENOUS PROTEIN | LONZA AG (CH) | 2026-03-05 | — | — | US | disclosed |
| US-12534511-B2 | Serum albumin-binding fibronectin type III domains | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-01-27 | — | — | US | disclosed |
| US-12529088-B2 | Helper factors for expressing proteins in yeast | LONZA LTD (CH) | 2026-01-20 | — | — | US | disclosed |
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | disclosed |
| WO-2025264860-A2 | METHODS OF TREATING POST-COVID AIRWAY DISEASE | YALE UNIVERSITY (US) | 2025-12-26 | — | — | WO | disclosed |
| EP-3966201-A1 | THIOSEMICARBAZATES AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| CN-114126619-A | Compounds for the synthesis of peptidomimetics | 范因斯坦医学研究院 | 2022-03-01 | — | — | CN | disclosed |
| CN-108218849-B | Novel inhibitors | 维沃永治疗公众有限公司 | 2022-03-01 | — | — | CN | disclosed |
| US-20220049275-A1 | SSI CELLS WITH PREDICTABLE AND STABLE TRANSGENE EXPRESSION AND METHODS OF FORMATION | LONZA AG (CH) | 2022-02-17 | — | — | US | disclosed |
| US-20220042064-A1 | CARBON-SOURCE REGULATED PROTEIN PRODUCTION IN A RECOMBINANT HOST CELL | LONZA LTD (CH) | 2022-02-10 | — | — | US | disclosed |
| EP-3947695-A1 | MUT- METHYLOTROPHIC YEAST | Universität für Bodenkultur Wien (AT) | 2022-02-09 | — | — | EP | disclosed |
| CN-114026239-A | MUT-methanol nutritional yeast | 维也纳自然资源与生命科学大学 | 2022-02-08 | — | — | CN | disclosed |
| CN-114026213-A | Continuous blade type impeller | 龙沙有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-11236520-B2 | Customizable facility | LONZA LTD (CH) | 2022-02-01 | — | — | US | disclosed |
| EP-3942014-A1 | CONTINUOUS BLADE IMPELLER | Lonza Ltd. (CH) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | GLS, GLS2, SULT1E1 | GRIN2D 244/4885GRIN3B 1148/4885GRIN1 157/4885 |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | GRIN2D 4/4885GRIN3B 27/4885GRIN1 8/4885 |
| US-12534511-B2 | Serum albumin-binding fibronectin type III domains | FN1, ALB, FGB | GRIN2D 4741/4885GRIN3B 4279/4885GRIN1 4544/4885 |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | NPR1, NGLY1, DDAH1 | GRIN2D 2136/4885GRIN3B 1231/4885GRIN1 882/4885 |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | TST, THRB, HSPB1 | GRIN2D 2602/4885GRIN3B 2523/4885GRIN1 2588/4885 |
| US-20260062709-A1 | METHODS FOR IMPROVING PRODUCTION OF BIOLOGICAL PRODUCTS BY REDUCING THE LEVEL OF ENDOGENOUS PROTEIN | MRPL21, SET, RPS27A | GRIN2D 4520/4885GRIN3B 4770/4885GRIN1 4872/4885 |
| US-12529088-B2 | Helper factors for expressing proteins in yeast | UPF1, ILF3, YIF1A | GRIN2D 4865/4885GRIN3B 4654/4885GRIN1 4710/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | GRIN2D 742/4885GRIN3B 464/4885GRIN1 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.